Seeking Alpha

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including ...

JERUSALEM, June 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (BVXV) , a biotechnology company focused on developing, manufacturing, and commercializing innovative ...
FierceBiotech

Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators

Junshi Biosciences has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval. The Shanghai-headquartered company ...
BioWorld

Scinai reports in vivo results for anti-IL-17A/F VHH antibody in psoriatic human skin model

Scinai Immunotherapeutics Ltd. has reported successful in vivo preclinical study results for its anti-IL-17A/F VHH antibody fragment (NanoAb) as a local intralesional biological treatment for mild to ...
EurekAlert!

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing ...
Business Wire

Ensemble Therapeutics Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing Ensemblins TM, a novel class of small molecule therapeutics with the power of biologics, announced today ...